StockStory
Q3 Medical Devices & Supplies - Cardiology, Neurology, Vascular Earnings: ICU Medical (NASDAQ:ICUI) Impresses
📈
AI Sentiment
Highly Positive
8/10
- Home
- ICUI
ICUI
ICU Medical Inc.
as of 11-28-2025 12:23pm EST
$147.56
$1.58
-1.06%
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (43% of consolidated revenue), infusion systems (28%), and vital care (29%). The combined entity remains primarily US-focused, generating over 63% of its sales domestically.
Chart Type:
Time Range:
| Founded: | 1984 | Country: | United States |
| Employees: | N/A | City: | SAN CLEMENTE |
| Market Cap: | 3.2B | IPO Year: | 1992 |
| Target Price: | $183.60 | AVG Volume (30 days): | 317.4K |
| Analyst Decision: | Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.31 | EPS Growth: | N/A |
| 52 Week Low/High: | $107.00 - $175.51 | Next Earning Date: | 11-06-2025 |
| Revenue: | $2,320,363,000 | Revenue Growth: | -0.84% |
| Revenue Growth (this year): | -6.13% | Revenue Growth (next year): | -1.30% |
AI-Powered ICUI Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 3 days ago
AI Recommendation
hold
Model Accuracy: 76.00%
76.00%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of ICU Medical Inc. (ICUI)
Woolson Daniel
Sell
VP, GM-Infusion Capital
ICUI Nov 25, 2025
Avg Cost/Share
$152.35
Shares
2,897
Total Value
$441,364.32
Owned After
11,297
SEC Form 4
Sanzone Virginia Ruth
Sell
VP, General Counsel
ICUI Nov 11, 2025
Avg Cost/Share
$142.35
Shares
930
Total Value
$132,380.85
Owned After
5,456
SEC Form 4
FINNEY ELISHA W
Sell
Director
ICUI Nov 11, 2025
Avg Cost/Share
$140.42
Shares
1,285
Total Value
$180,439.70
Owned After
3,995
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Woolson Daniel | ICUI | VP, GM-Infusion Capital | Nov 25, 2025 | Sell | $152.35 | 2,897 | $441,364.32 | 11,297 | |
| Sanzone Virginia Ruth | ICUI | VP, General Counsel | Nov 11, 2025 | Sell | $142.35 | 930 | $132,380.85 | 5,456 | |
| FINNEY ELISHA W | ICUI | Director | Nov 11, 2025 | Sell | $140.42 | 1,285 | $180,439.70 | 3,995 |
Latest ICU Medical Inc. News
ICUI Breaking Stock News: Dive into ICUI Ticker-Specific Updates for Smart Investing
MT Newswires
ICU Medical Insider Sold Shares Worth $441,364, According to a Recent SEC Filing
âž–
AI Sentiment
Neutral
5/10
Simply Wall St.
ICU Medical (ICUI): Is the Recent Share Price Rally Backed by Undervalued Fundamentals?
📊
AI Sentiment
Positive
7/10
StockStory
Myriad Genetics, Neogen, ICU Medical, HCA Healthcare, and Universal Health Services Stocks Trade Up, What You Need To Know
📈
AI Sentiment
Highly Positive
9/10
Compare ICUI vs Leading Stocks
See how ICUI stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "ICUI ICU Medical Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.